UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
MB Number:	3235-0287					
stimated average burden						
oure por rocponeo	0.5					

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(11mt of 1y	pe response	23)														
1. Name and Address of Reporting Person * Kelly Scott A.			2. Issuer Name and Ticker or Trading Symbol CytoDyn Inc. [CYDY]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle) 1111 MAIN STREET, SUITE 660				3. Date of Earliest Transaction (Month/Day/Year) 04/10/2017							Officer (give title below) Other (specify below)					
(Street)			4	4. If Amendment, Date Original Filed(Month/Day/Year)						_X_ F	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
VANCO	JVER, WA	A 98660									F	offit filled by F	nore man One i	xeporting reison		
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui						Acquired,	ired, Disposed of, or Beneficially Owned					
(Instr. 3) Date		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date ary (Month/Day/Y		Date, if	Cod		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		C(D) Own Tran	ed Follow saction(s)			Ownership Form:	Beneficial	
					y/Year)	C	Code V	Amou	(A) or	Price	str. 3 and 4)			Direct (D) or Indirect (I) (Instr. 4)	Ownership Instr. 4)	
Reminder:	Report on a	separate line for eac	h class of securities	beneficia	ally	owned		tly or indirec	tly. ns wi	ho respond	to the co	equired	to respon	d unless th	SEC 1	474 (9-02)
								quired, Disp	osed	ays a curre of, or Benefi rtible securit	icially Ow	ıed				
1. Title of Derivative Security (Instr. 3)	Conversion	ise (Month/Day/Year)	Execution Date, if							7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownersh Form of Derivativ Security: Direct (Dor Indirect		
				Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$ 0.61	04/10/2017		A		7,123		05/31/201	7(1)	04/10/2027	Common Stock	7,123	\$ 0	7,123	D	
• • • • • • • • • • • • • • • • • • • •	ting O	wners														

D (1 0 N (41)	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Kelly Scott A. 1111 MAIN STREET, SUITE 660 VANCOUVER, WA 98660	X					

# **Signatures**

/s/ Michael D. Mulholland, as attorney-in-fact	04/12/2017		
**Signature of Reporting Person	Date		

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Subject to stockholder approval of the increase in the number of shares of common stock authorized for issuance under the CytoDyn Inc. 2012 Equity Incentive Plan, as amended, at the next annual meeting.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.